Israel & United States — Food and Drug Administration
12 shared events · Importance 3 · Last updated May 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
Israel: Israel is seeking talks with Lebanon, contributing to easing worries over the Middle East conflict and positively influencing market sentiment.
United States — Food and Drug Administration: The United States — Food and Drug Administration approved Eli Lilly and Company's weight loss pill, Foundayo, impacting the pharmaceutical market.
Apr 01, 2026 · 14 articles
International
Israel: Israel is engaged in military exchanges with Iran and Hezbollah, contributing to regional instability and affecting global markets.
United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.
May 18, 2026 · 316 articles
Business
Israel: Israel is identified as a global market where FDA approval could accelerate regulatory pathways for Jyong Biotech's products.
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) approval is a critical milestone for Jyong Biotech's lead drug candidates, as it enables market access and sets a precedent for global regulatory pathways.
May 29, 2026 · 7 articles
Business
Israel: Imlifidase is approved in Israel, further expanding its international market reach.
United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the Biologics License Application for imlifidase in February 2026, indicating potential future market expansion for the drug in the US.
May 27, 2026 · 6 articles
Business
Israel: Israel is another market where Idefirix is approved, contributing to the product's international availability.
United States — Food and Drug Administration: The FDA's acceptance of the BLA and PDUFA date of December 19, 2026, are key upcoming regulatory milestones for GT Biopharma in the US market.
Aug 18, 2026 · 6 articles
Regulatory
Israel: Country where trofinetide is already marketed.
United States — Food and Drug Administration: The FDA previously approved trofinetide in the US, establishing its efficacy and safety.
Aug 24, 2026 · 7 articles
Business
Israel: Israel is the location of Can-Fite BioPharma Ltd. and the Davidoff Institute of Oncology, Rabin Medical Center, where the study lead is based.
United States — Food and Drug Administration: The United States — Food and Drug Administration previously granted Namodenoson Orphan Drug Designation and Fast Track Designation for hepatocellular carcinoma, indicating its potential regulatory path.
Jul 01, 2026 · 6 articles
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the Biologics License Application for imlifidase, setting a PDUFA action date for December 19, 2026.
May 25, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Israel and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard